---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-038380"
form_type: "8-K/A"
ticker: "XTNT"
cik: "0001453593"
company_name: "Xtant Medical Holdings, Inc."
filed_at: "2023-10-26T23:59:59+00:00"
generated_at: "2026-06-09T08:24:35.688653+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Xtant acquires Surgalign assets; Surgalign reports Q1 2023 revenue $16.7M, net income $4.1M with going concern doubt

## Summary
- Surgalign Q1 2023 revenue $16.7M (down 19% YoY); net income $4.1M included $12.6M gain on Coflex sale.
- Surgalign had $22.4M cash, $620M accumulated deficit; management expressed substantial doubt about going concern.
- Surgalign not in compliance with Nasdaq listing requirements as of April 2023.
- Xtant acquired Coflex/Cofix product lines for $17M cash; this 8-K/A provides Surgalign historical financials.
- Pro forma condensed combined financial statements filed, giving effect to the acquisition.

## SEC filing metadata
- accession: 0001493152-23-038380
- form_type: 8-K/A
- ticker: XTNT
- cik: 0001453593
- company_name: Xtant Medical Holdings, Inc.
- filed_at: 2023-10-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453593/000149315223038380/0001493152-23-038380-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453593/000149315223038380/form8-ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-038380
- JSON: https://secwatch.observer/filing/0001493152-23-038380.json
- Plain text: https://secwatch.observer/filing/0001493152-23-038380.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.